Dr. O'Brien on Sequencing Small Molecule Inhibitors in CLL

Susan M. O'Brien
Published: Monday, Aug 06, 2018



Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses sequencing small molecule inhibitors in chronic lymphocytic leukemia (CLL).

Ibrutinib (Imbruvica) is currently the only small molecule inhibitor with a frontline label, so that tends to be the preferred frontline agent. Although, there is a role for chemotherapy, explains O’Brien. Many physicians will use duvelisib and fludarabine-cyclophosphamide-rituximab (FCR) who have a mutated IGHV gene, as many studies have shown a plateau on the progression-free survival curve in patients with a mutation in IGHV. However, where physicians do not want to use FCR, ibrutinib will be used, says O’Brien. This decision is often based on mutation status as well as 17p deletion status, as chemotherapy is ineffective in patients with 17p deletion.

If the patient is intolerant to ibrutinib, idelalisib (Zydelig) plus rituximab (Rituxan) or venetoclax (Venclexta) can easily be adopted, explains O’Brien. However, patients who are refractory to ibrutinib may not experience lasting response with idelalisib. Whereas, venetoclax in the setting of ibrutinib resistance can induce durable responses alongside minimal residual disease negativity, says O’Brien.
SELECTED
LANGUAGE


Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses sequencing small molecule inhibitors in chronic lymphocytic leukemia (CLL).

Ibrutinib (Imbruvica) is currently the only small molecule inhibitor with a frontline label, so that tends to be the preferred frontline agent. Although, there is a role for chemotherapy, explains O’Brien. Many physicians will use duvelisib and fludarabine-cyclophosphamide-rituximab (FCR) who have a mutated IGHV gene, as many studies have shown a plateau on the progression-free survival curve in patients with a mutation in IGHV. However, where physicians do not want to use FCR, ibrutinib will be used, says O’Brien. This decision is often based on mutation status as well as 17p deletion status, as chemotherapy is ineffective in patients with 17p deletion.

If the patient is intolerant to ibrutinib, idelalisib (Zydelig) plus rituximab (Rituxan) or venetoclax (Venclexta) can easily be adopted, explains O’Brien. However, patients who are refractory to ibrutinib may not experience lasting response with idelalisib. Whereas, venetoclax in the setting of ibrutinib resistance can induce durable responses alongside minimal residual disease negativity, says O’Brien.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x